- Home
- OPRX vs TLSA Comparison
OPRX vs TLSA Comparison
Compare OPRX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- TLSA
- Stock Information
- Founded
- OPRX 2006
- TLSA 2013
- Country
- OPRX United States
- TLSA United Kingdom
- Employees
- OPRX N/A
- TLSA N/A
- Industry
- OPRX Business Services
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- OPRX Consumer Discretionary
- TLSA Health Care
- Exchange
- OPRX Nasdaq
- TLSA Nasdaq
- Market Cap
- OPRX 154.0M
- TLSA 87.8M
- IPO Year
- OPRX N/A
- TLSA 2000
- Fundamental
- Price
- OPRX $8.72
- TLSA $1.36
- Analyst Decision
- OPRX Buy
- TLSA
- Analyst Count
- OPRX 8
- TLSA 0
- Target Price
- OPRX $9.06
- TLSA N/A
- AVG Volume (30 Days)
- OPRX 231.5K
- TLSA 332.0K
- Earning Date
- OPRX 05-12-2025
- TLSA 05-09-2025
- Dividend Yield
- OPRX N/A
- TLSA N/A
- EPS Growth
- OPRX N/A
- TLSA N/A
- EPS
- OPRX N/A
- TLSA N/A
- Revenue
- OPRX $92,127,000.00
- TLSA N/A
- Revenue This Year
- OPRX $12.12
- TLSA N/A
- Revenue Next Year
- OPRX $10.87
- TLSA N/A
- P/E Ratio
- OPRX N/A
- TLSA N/A
- Revenue Growth
- OPRX 28.81
- TLSA N/A
- 52 Week Low
- OPRX $3.78
- TLSA $0.54
- 52 Week High
- OPRX $14.13
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- OPRX 54.56
- TLSA 63.09
- Support Level
- OPRX $8.09
- TLSA $0.76
- Resistance Level
- OPRX $8.92
- TLSA $1.53
- Average True Range (ATR)
- OPRX 0.64
- TLSA 0.14
- MACD
- OPRX -0.07
- TLSA 0.06
- Stochastic Oscillator
- OPRX 69.34
- TLSA 78.75
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.